Curis says six patients consented in TakeAim CLL study, keeps July dosing target

The biotech reaffirmed plans to dose five chronic lymphocytic leukemia patients by the end of July 2026 and still expects initial data in December 2026.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.